Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apple

American Electric Power Company

Amgen

Costco

Cintas Corp

W.W. Grainger

Intel

Landstar System

Norfolk Southern

Visa

WEC Energy Group

In this article series, we provide a summary of upcoming ex-dividend dates.

Upcoming Ex-Dividend Dates: February 3-12, 2021

Forget Day Trading! Buy and Hold These 2 Stocks

INDIANAPOLIS, Feb. 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to provide Hoosiers with access to important COVID-19...

Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients

Pharmaceutical manufacturer Eli Lilly and Co. (NYSE:LLY) has released strong earnings thanks to high demand for cancer and diabetes treatments alongside government purchases of its Covid-19 antibody treatment.

Eli Lilly Tops Estimates With Government Purchases of Covid Treatment

Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2020 Results - Earnings Call Transcript

The shares of Eli Lilly And Co (NYSE:LLY) are down 2.1% at $205.80 this afternoon -- likely due to some broad-market headwinds  -- despite earlier surging to an all-time high of $218.

Drug Stock Reverses from Record Highs Despite Blowout Earnings

December's sales were as good as Wall Street expected, but profits came in about 9% better than the forecasts of analysts polled by FactSet.

Lilly Reports Strong Sales, Boosted by Covid Antibodies

Lilly (LLY) beats fourth-quarter estimates for both earnings and sales. Stock up in pre-market trading.

Eli Lilly (LLY) Q4 Earnings Top, COVID-19 Antibody Boosts Sales

Regeneron Pharmaceuticals

There's some good news and some bad news.

Can Eli Lilly and Regeneron Antibody Treatments Beat New COVID Strains?

Shares of Eli Lilly (NYSE:LLY) decreased 0.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 58.96% year over year to $2.75, which beat the estimate of $2.35.

Recap: Eli Lilly Q4 Earnings

Eli Lilly beat earnings and sales views, but 2021 guidance was a little light at the midpoint. Lilly shares rose slightly.

Eli Lilly Stock Rises Near Highs As Lilly Earnings Beat Views

Eli Lilly and Co posted a 41.5% rise in fourth-quarter profit on Friday, helped by higher demand for its diabetes drugs and a successful launch of its COVID-19 antibody treatment.

Eli Lilly profit rises 41.5% as COVID-19 drug lifts sales

Eli Lilly & Co. reported Friday a big fourth-quarter profit beat and revenue that rose 22% to top forecasts, as it recognized $850 million in U.S. revenue for bamlanivimab, the drugmaker's treatment for mile to moderate COVID-19 that has been granted Emergency Use Authorization. The company said it has delivered 950,000 bamlanivimab doses to the U.S. government, and has agreed to deliver 500,000 more doses no later than March 31.

Eli Lilly beats profit and sales forecasts, to deliver 500,000 more COVID-19 treatment doses by end of March

INDIANAPOLIS, Jan. 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2020. $ in millions, except per share data Fourth Quarter % Full Year % 2020 2019 Change 2020 2019 Change Revenue $ 7,440.0 $ 6,114.0 22%...

Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results

GlaxoSmithKline

Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.

Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen

Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Lilly (LLY) This Earnings Season?

INDIANAPOLIS and TOKYO, Jan. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an orally bioavailable P2X7 receptor...

Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate

Eli Lilly's (LLY) combination of its COVID-19 antibodies bamlanivimab (LY-CoV555) plus etesevimab (LY-CoV016) reduces COVID-19-related hospitalizations and deaths by 70%.

Lilly's (LLY) Bamlanivimab Combo Lowers COVID-19 Hospitalization

Bristol-Myers

We think that Bristol Myers Squibb currently is a better pick compared to Eli Lilly & Company. BMY stock trades at about 3.7x trailing Revenues, compared to around 8.1x for LLY.

Bristol Myers Squibb Stock Can Offer Better Returns Over Eli Lilly

Vir Biotechnology

INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk...

Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Eli Lilly is back with another round of promising data on its Covid-19 antibody therapies.

Eli Lilly and Regeneron Report More Positive Data on Covid-19 Antibody Cocktails

Shares of Eli Lilly & Co. were up 0.3% in premarket trading on Tuesday after the drugmaker said combining two of its experimental COVID-19 antibody treatments can reduce hospitalizations and deaths in high-risk patients by up to 70%, based on findings from a Phase 3 clinical trial. The combination of bamlanivimab, which has received emergency use authorization in the U.S. as a standalone treatment for some COVID-19 patients, and the still-investigational etesevimab is being tested in about 1,000 patients.

Lilly says late-stage study showed combo therapy can reduce deaths and hospitalizations in COVID-19 patients

INDIANAPOLIS, Jan. 26, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, "events") in high-risk patients recently diagnosed with COVID-19, meeting the primary...

New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.

Will Eli Lilly (LLY) Beat Estimates This Earnings Season?

Gilead Sciences

These are the recently approved treatments biotech investors want to keep their eyes on in 2021.

News for Eli Lilly Stock (LLY)